Dean Li invites another under-the-radar biotech to Merck's dealmaking table as Amathus signs neurodegeneration pact
Less than three months since taking over from Roger Perlmutter, new Merck R&D chief Dean Li continues to wheel and deal.
Li and the Merck team have agreed to a new collaboration with little-known biotech Amathus Therapeutics, promising an undisclosed upfront amount in addition to an option to acquire the company. Should the option be exercised, Amathus would be in line for up to $500 million in milestones per program.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.